A covid-19 vaccine candidate developed by U.S. pharmacist Pfizer and German biotech company BioNTech has yielded positive results during the first tests, according to the findings. published in a statement.
As part of the BNT162 research program, the company has created four candidate vaccines against SARS-CoV-2, the so-called BNT162b1 showing promising results in neutralizing the protein used by the virus to adhere to the surface of human cells. .
According to Ugur Sahin, CEO and co-founder of BioNTech, the preliminary data obtained so far “is encouraging, as it shows that BNT162b1 [] It is capable of producing neutralizing antibody responses in humans at levels equal to or greater than “those produced by sera created from the plasma of people who have recovered from the disease.
Currently, BNT162b1 is in test phases 1/2 in the US, that is, the safety of the vaccine, the tolerability of patients to the drug, as well as the immunogenicity it produces at different doses, are being evaluated.
The candidate vaccine has not yet been approved for distribution, however, if the studies continue to be successful and are authorized by the competent authorities, “companies expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion. dose by the end of 2021. “
–
– .